title: Vaccination of dogs with canine parvovirus type 2b (CPV-2b) induces neutralising antibody responses to CPV-2a and CPV-2c.
abstract: Since the identification of canine parvovirus type 2, three variants have subsequently been observed differing from the historical CPV-2 and each other by 1-2 amino acids only. As a result there has been considerable research into differential diagnostics, with some researchers indicating there is a need for new vaccines containing different strains of CPV-2. In this study we investigated whether vaccination with a CPV-2b containing vaccine would induce cross-reactive antibody responses to the other CPV-2 variants. Two studies where dogs were vaccinated with a multivalent vaccine, subsequently challenged with CPV-2b and sera samples analysed are presented. Six week old pups with defined serological status were vaccinated twice, three weeks apart and challenged either 5 weeks (MDA override study) or one year after vaccination (duration of immunity study). Sera samples were collected before each vaccination and at periods throughout each study. In each study the antibody profiles were very similar; serological responses against CPV-2a, CPV-2b and CPV-2c were higher than those for CPV-2. Nevertheless, responses against CPV-2 were well above levels considered clinically protective. In each study dogs also showed a rapid increase in antibody titres following vaccination, reached a plateau following second vaccination with a slight decline to challenge after which rapid anamnestic responses were seen. Evaluation of the serological responses suggests vaccination with CPV-2b would cross-protect against CPV-2a and CPV-2c, as well as against CPV-2 which is now extinct in the field. In conclusion we have demonstrated that vaccination of minimum aged dogs with a multivalent vaccine containing the CPV-2b variant strain will induce serological responses which are cross-reactive against all currently circulating field strains, CPV-2a and CPV-2c, and the now extinct field strain CPV-2.
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 1930 Zaventem, Belgium. Electronic address: stephen.wilson@zoetis.com.
authors.forename: Stephen
authors.initials: S
authors.lastname: Wilson
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 1930 Zaventem, Belgium.
authors.forename: Joanna
authors.initials: J
authors.lastname: Illambas
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 1930 Zaventem, Belgium.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Siedek
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, Sandwich, UK.
authors.forename: Catrina
authors.initials: C
authors.lastname: Stirling
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 1930 Zaventem, Belgium.
authors.forename: Anne
authors.initials: A
authors.lastname: Thomas
authors.affiliation: Bioveta a.s., Komenského 212, 683 23 Ivanovice na Hané, Czech Republic.
authors.forename: Edita
authors.initials: E
authors.lastname: Plevová
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, Kalamazoo, MI 49007, USA.
authors.forename: Gordon
authors.initials: G
authors.lastname: Sture
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 1930 Zaventem, Belgium.
authors.forename: Jeremy
authors.initials: J
authors.lastname: Salt
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D056738:Cross Protection; D004283:Dog Diseases / Q000276:immunology / Q000517:prevention & control*; D004285:Dogs / Q000276:immunology*; D010322:Parvoviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D017993:Parvovirus, Canine / Q000145:classification*; D014611:Vaccination / Q000662:veterinary; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D014765:Viral Vaccines
keywords: Canine; Cross-protection; Parvovirus